Axogen Inc vs Blackrock Inc — how do they compare? Axogen Inc trades at $38.5 (market cap $2.06B), while Blackrock Inc trades at $1,065.01 (market cap $158.94B). The key difference: Blackrock Inc is far larger — about 77.2× Axogen Inc's market cap, and Blackrock Inc pays a 2.24% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | BLK | |
|---|---|---|
Market Cap | $2.06B | $158.94B |
Sector | Technology | Financials |
52-Week High | $46.19 | $1.20K |
52-Week Low | $11.28 | $922.90 |
Enterprise Value | $1.98B | $160.76B |
Volume | — | 641,547 |
Dividend Yield | — | 2.24% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
BlackRock (BLK) trades at $1,031.56, down 0.44% on the day, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results anticipated. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. The company maintains robust profitability metrics, including a 24.4% net income margin and 11.95% ROE. Recent news highlights the launch of a new Nasdaq-100 ETF, IQQ, challenging Invesco's QQQ.
The outlook for BLK remains positive, driven by earnings momentum, strategic ETF expansion, and solid institutional support. Key risks include market volatility affecting asset management fees and competitive pressures in the ETF space. With 76% of analysts rating it a Buy and a consensus price target of $1,290, the stock presents a compelling opportunity for growth-oriented investors, though monitoring Q2 earnings and macroeconomic trends is essential.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →